FDA Emphasizes Efficiency In 522 Surveillance Order Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA is emphasizing the need for “early and ongoing” interaction between regulators and device companies targeted by the agency in Section 522 post-market surveillance orders in a draft guidance issued Aug. 16.